VISCHER has advised TargImmune on the deal.TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Federica Tiefenthaler
…
This content is for Standard 1 Year members only. LoginJoin Now